Palantir Technologies Inc. (NYSE:PLTR) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to support the agency's mission to accelerate better health outcomes.
CEOs of Palantir, Oracle, and Pfizer lobbied US senators for support of Israel during Gaza invasion and discussed solutions for hostages held by Hamas.
Palantir shares closed Monday up 6.15% after Argus Research analyst Joseph Bonner initiated coverage on the stock with a Buy rating and announced a price target of $29, highlighting momentum around the company's commercial business.
Palantir Technologies shares are trading higher Monday after Argus Research analyst Joseph Bonner initiated coverage on Palantir with a Buy rating and announced a price target of $29. Here's a look at the analyst's note: